Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Actuate Therapeutics, Inc. (ACTU) vs NewcelX Ltd. (NCEL)

Actuate Therapeutics, Inc. and NewcelX Ltd. are both Biotechnology companies. Actuate Therapeutics, Inc. and NewcelX Ltd. are of similar size ($15.9M and $15.6M). Across the 9 metrics below, Actuate Therapeutics, Inc. leads on 5 and NewcelX Ltd. on 4.

Valuation

Metric ACTU NCEL Biotechnology median
P/E n/m n/m 7.88
P/S n/m n/m 11.47
P/B 16.41 5.44 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales n/m n/m 10.73
Earnings yield (127.94%) (51.86%) (28.84%)
Free cash flow yield (122.20%) (36.48%) (23.03%)

Profitability

Metric ACTU NCEL Biotechnology median
Gross margin — 0.00% 65.16%
Operating margin 0.00% — 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 2,457.65% 0.00% (57.72%)
Return on assets (336.18%) 0.00% (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ACTU NCEL Biotechnology median
Revenue growth (TTM) — — 5.64%
EPS growth (last fiscal year) 67.48% 11.18% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric ACTU NCEL Biotechnology median
Debt to equity 0.00 0.06 0.00
Current ratio 1.25 0.40 4.73
Net debt to EBITDA 0.59 0.74 0.96

Dividend

Metric ACTU NCEL Biotechnology median
Dividend yield — — 2.10%
Payout ratio — 0.00 0.00

Size

Metric ACTU NCEL Biotechnology median
Market cap 15.85m 15.56m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack